Introduced

Passed House

Passed Senate

Became law

Adjourned sine die. The bill was pending when the session ended, so it did not pass.

Last action · January 14, 2026

To Health Services (H)

Introduced January 7, 2026

House

Adjourned Sine Die

2026 Regular Session

HB153

AN ACT relating to administrative regulations for medications for substance use disorder and declaring an emergency.

Create a new section of KRS Chapter 13A to find 201 KAR 9:270 and 201 KAR 20:065 deficient and void; create new sections of KRS Chapters 311, 313, 314, and 315 to establish that the State Board of Medical Licensure, Board of Dentistry, Kentucky Board of Nursing, and Kentucky Board of Pharmacy shall not promulgate administrative regulations that restrict or limit the prescribing, dispensing, or administering of buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or any other Schedule III, IV, or V medication approved by the United States Food and Drug Administration for the treatment of a substance use disorder; EMERGENCY.

Substance Use Administrative Regulations and Proceedings Drugs and Medicines Effective Dates, Emergency Health and Medical Services Health Care Professionals Nurses Opioids Pharmacists Physicians Public Health

Read the full text Kentucky Legislature LegiScan

AI-generated. Always verify with primary sources

Plain-language summary

Beta

This bill would cancel two existing state regulations and prohibit Kentucky's medical, nursing, pharmacy, and dentistry licensing boards from creating rules that limit how certain medications used to treat substance use disorder — including buprenorphine — can be prescribed, dispensed, or administered. It is filed as an emergency measure, meaning it would take effect immediately if signed into law. The goal is to remove regulatory barriers that may restrict patient access to FDA-approved medications for…

Open official bill text (PDF)·Report a problem with the summary